IP Library › Granted Patent US 8,722,719
Granted Patent B2
US 8,722,719 · App. 13/878,131 · Granted May 13, 2014

Amine compound and use for same

Inventors: Ryo Matsui (Tokyo, JP); Toru Yamazaki (Tokyo, JP); Shigeyuki Kikumoto (Tokyo, JP)
Assignee: Kureha Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,719
App. No.
13/878,131
Granted
May 13, 2014
Kind
B2
Abstract

Provided is an ester of 3-[(4-dipropylamino-butyl)(4-{[(1H-imidazole-2-ylmethyl)(1-methyl-1H-imidazole-2-ylmethyl)amino]methyl}benzyl)amino]propionic acid which is easily hydrolyzed in serum. The amine compound of the present invention is an ester compound represented by general formula (1). (In general formula (1), n is 1-4, and R 1 and R 2 represent an alkyl group having 1-3 carbon atoms.)

Claims (12)

1. An amine compound represented by a general formula (1) or a pharmacologically acceptable salt thereof,

wherein n is an integer from 1 to 4, and R 1 and R 2 represent an alkyl group having 1 to 3 carbon atoms.

2. An amine compound or a pharmacologically acceptable salt thereof according to claim 1 , wherein n in the general formula (1) is 2 or 3.

3. An amine compound or a pharmacologically acceptable salt thereof according to claim 2 , wherein n in the general formula (I) is 2, and R 1 and R 2 in the general formula (1) represent a methyl group or an ethyl group.

4. An amine compound or a pharmacologically acceptable salt thereof according to claim 1 , wherein the amine compound represented by the general formula (1) is 2-dimethylaminoethyl 3-[(4-dipropylaminobutyl)(4-{[(1H-imidazol-2-ylmethyl)(1-methyl-1H-imidazol-2-ylmethyl)amino]methyl}benzyl)amino]propionate.

5. An amine compound or a pharmacologically acceptable salt thereof according to claim 4 , wherein the pharmacologically acceptable salt is a citrate of 2-dimethylaminoethyl 3-[(4-dipropylaminobutyl)(4-{[(1H-imidazol-2-ylmethyl)(1-methyl-1H-imidazol-2-ylmethyl)amino]methyl}benzyl)amino]propionate.

6. A pharmaceutical composition comprising as an active ingredient the amine compound or the pharmacologically acceptable salt thereof according to claim 1 .

7. A pharmaceutical composition according to claim 6 , comprising as a prodrug the amine compound or the pharmacologically acceptable salt thereof according to claim 1 .

8. A CXCR4 antagonist comprising as an active ingredient the amine compound or the pharmacologically acceptable salt thereof according to claim 1 .

9. An antiviral drug comprising as an active ingredient the amine compound or the pharmacologically acceptable salt thereof according to claim 1 .

10. An anti-rheumatic disease agent based on CXCR4 antagonism, the anti-rheumatic disease agent comprising as an active ingredient the amine compound or the pharmacologically acceptable salt thereof according claim 1 .

11. An anti-metastatic disease agent based on CXCR4 antagonism, comprising as an active ingredient the amine compound or the pharmacologically acceptable salt thereof according to claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2013
From: MATSUI, RYO; YAMAZAKI, TORU; KIKUMOTO, SHIGEYUKI
To: KUREHA CORPORATION
Reel/Frame 030468/0389 →
Priority Claims (1)
JP 2010-226370 · Oct 6, 2010 · national
Continuity (1)
Related Publication 20130245280A1 · Sep 19, 2013